Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0151744 (myocardial ischemia)
 31,282 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Idiopathic pulmonary fibrosis (IPF) is associated with a fatal prognosis and manifests in patients over 60 years old who may have comorbidities. The prevalence and impact of comorbidities on the clinical course of IPF is unclear.This systematic literature review examined the prevalence of comorbidities and mortality associated with comorbidities in IPF patients. Relevant observational studies published in English from January 1990 to January 2015 identified via MEDLINE and EMBASE were included; bibliographies of articles were also searched.Among the 126 studies included, prevalence of pulmonary hypertension (PH) was 3-86%, 6-91% for obstructive sleep apnoea, 3-48% for lung cancer and 6-67% for chronic obstructive pulmonary disease (COPD). Nonrespiratory comorbidities included ischaemic heart disease (IHD) (3-68%) and gastro-oesophageal reflux (GER) (0-94%). Mortality was highest among patients with IPF and lung cancer. Most studies assessed relatively small samples of patients with IPF.PH, COPD, lung cancer, GER and IHD are significant comorbidities; differences in IPF severity, case definitions and patient characteristics limited the comparability of findings. The identification and prompt treatment of comorbidities may have a clinically significant impact on overall outcome that is meaningful for patients with IPF.
 ...
PMID:Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. 2642 23

We report a case of an 83-year-old man with history of coronary artery disease and gastroesophageal reflux disease (GERD) who presented with sudden onset nocturnal dyspnea. He was diagnosed with non-ST elevation myocardial infarction based on the electrocardiographic changes and cardiac biomarker elevation. Cardiac catheterization revealed chronic three-vessel coronary artery disease, with 2 patent grafts and 2 chronically occluded grafts. While at the hospital, the patient experienced a similar episode of nocturnal dyspnea, prompting a barium esophagram, which was suggestive of a stricture in the distal esophagus from long-standing GERD. We hypothesized that he had myocardial ischemia due to increased oxygen demand from uncontrolled GERD symptoms. He had no further ischemic episodes after increasing the dose of antireflux medication over a 6-month follow-up. After presenting our case, we review the literature on this atypical presentation of GERD causing acute coronary syndrome and discuss potential mechanisms.
...
PMID:Acute Coronary Syndrome: An Unusual Consequence of GERD. 2668 58

Ischemic heart disease (IHD) and gastroesophageal reflux disease (GERD) are among the most common diseases worldwide, which in a considerable percentage of cases occur together, thus complicating symptoms, posing problems for timely diagnosis and hindering development of a comprehensive treatment regimen for both diseases. Research has shown that endothelial dysfunction is one of the major pathophysiological mechanisms in the development of IHD. Endothelial dysfunction also affects regional perfusion of the esophagus, thus compromising esophageal tissue defense mechanisms. The aim of our study was to investigate the role of endothelial dysfunction in the mechanisms of GERD development in patients with IHD. For the purpose of this study, we collected data on serum levels of endothelin-1, nitric oxide metabolites and lipid peroxidation products, gastric pH, parameters of regional blood flow, and quality of life assessment. Study results revealed that in IHD patients with concomitant GERD, endothelial dysfunction manifested by a significant increase in the levels of endothelin-1 and lipid peroxidation products, with decreased levels of nitric oxide metabolites, regional blood flow and quality of life. These findings suggest that hypoxia of the esophageal mucosa, caused by endothelial dysfunction, leads to a decrease in the esophageal tissue resistance and to esophageal lower sphincter dysfunction, which, in turn, are the leading factors in the development of GERD.
 ...
PMID:The Role of Endothelial Dysfunction in the Mechanism of Gastroesophageal Reflux Disease Development in Patients with Ischemic Heart Disease. 2959 Jul 16

Helicobacter Pylori (HP) persistently colonizes the stomach in about 50% of the globe population and it is the main risk factor for peptic ulcer, as well as for gastric adenocarcinoma and MALT gastric lymphoma. The treatment for HP revolutionized the management of the peptic ulcer disease, providing permanent healing in many cases. Preventing colonization of HP would be the primary prevention of gastric malignancy and peptic ulceration. At the same time, the presence of HP provides protection for some diseases (gastroesophageal reflux disease and its complications, esophageal adenocarcinoma, asthma), the eradication of the microorganism having negative repercussions. HP has an increasingly recognized role in other extragastric pathologies. Thus, immune thrombocytopenic purpura has improved after treating HP infection. There are controversial association with ischemic heart disease and cerebrovascular disease. The current article highlights an important association between HP infection and a range of hepatobiliary disorders such as biliary lithiasis (where even an etiological role is involved), cholestatic syndromes (primary sclerosing cholangitis and primary biliary cholangitis), chronic hepatitis B virus, chronic hepatitis C virus, with an evolution towards cirrhosis and hepatocellular carcinoma.
 ...
PMID:The Association Between Helicobacter Pylori Infection and Liver and Biliary Tract Disorders. 3068 30

Idiopathic pulmonary fibrosis (IPF) is characterized by progressive parenchymal scarring, leading to dyspnoea, respiratory failure and premature death. Although IPF is confined to the lungs, the importance of IPF comorbidities such as pulmonary hypertension and ischaemic heart disease, lung cancer, emphysema/chronic obstructive pulmonary disease, gastroesophageal reflux, sleep apnoea and depression has been increasingly recognized. These comorbidities may be associated with increased mortality and significant loss of quality of life, so their identification and management are vital. The development of good-quality biomarkers could lead to numerous gains in the management of these patients. Biomarkers can be used for the identification of predisposed individuals, early diagnosis, assessment of prognosis, selection of best treatment and assessment of response to treatment. However, the role of biomarkers for IPF comorbidities is still quite limited, and mostly based on evidence coming from populations without IPF. The future development of new biomarker studies could be informed by those that have been studied independently for each of these conditions. For now, clinicians should be mostly attentive to clinical manifestations of IPF comorbidities, and use validated diagnostic methods for diagnosis. As research on biomarkers of most common diseases continues, it is expected that useful biomarkers are developed for these diseases and then validated for IPF populations. The reviews of this paper are available via the supplemental material section.
 ...
PMID:Comorbidity in idiopathic pulmonary fibrosis - what can biomarkers tell us? 3216 24

There is a significant data about overlap of functional dyspepsia (FD) and irritable bowel syndrome (IBS), however mostly the data is based on the previous diagnostic criteria and do not include other pathologies. In the previous researches there were no differential statistical analysis performed for different types of FD - postprandial distress syndrome (PDS) and epigastric pain syndrome (EBS). Aim of the study - to assess potential risk factors and the prevalence of comorbid conditions associated with FD and to compare their frequency with the same in the group with no dyspeptic complaints and in patients with different types of FD - PDS and EPS. This study was conducted as a retrospective database analysis of the patients with newly set diagnosis of FD and control group. For all the cases the information on demographic (working status, family status) and lifestyle characteristics (body mass index, smoking status, and alcohol consumption), and comorbidities were collected from the medical files. We statistically analyzed the presence of risk factors, comorbidity and its frequency in the patients with FD and compared the results with control group and in the groups with different types of FD according to the generally accepted standards. This study included 158 patients with PDS, 87 patients with EBS, and 90 volunteers with no dyspeptic complaints. Smoking, alcohol consumption, and family status were not associated with the risk of FD. The presence of sleep disorders and being unemployed increased the risk of FD. The comparison of the results of the patients with different types of FD demonstrated that there were no statistical difference in risk factors for the PDS and EPS. Gastroesophageal reflux disease (GERD), IBS, chronic gastritis and / or duodenitis, anxiety, and depression occur more frequently in the group of patients with FD. No association between autoimmune thyroiditis (AIT), arterial hypertension and ischemic heart disease (IHD) was evaluated. There was no statistical difference for the frequency of GERD, chronic gastritis and / or duodenitis, anxiety, AIT, arterial hypertension, and IHD in the patients with different types of FD. However, it was evaluated that IBS and depression occur more frequently in the group of patients with PDS, than in the patients with EPS.
 ...
PMID:RISK FACTORS AND COMORBIDITY IN DIFFERENT TYPES OF FUNCTIONAL DYSPEPSIA: RETROSPECTIVE COHORT ANALYSIS. 3327 May 86


<< Previous 1 2 3